Stockscreener 앱 받기
1.63
0.00%
0.00
전일 마감가:
$1.63
열려 있는:
$1.63
하루 거래량:
430.76K
Relative Volume:
0.05
시가총액:
$1.22B
수익:
$581.12M
순이익/손실:
$-212.92M
주가수익비율:
-5.9533
EPS:
-0.2738
순현금흐름:
$-174.22M
1주 성능:
-1.81%
1개월 성능:
-0.61%
6개월 성능:
+35.83%
1년 성능:
+12.41%
1일 변동 폭
$1.605
$1.63
1주일 범위
$1.58
$1.67
52주 변동 폭
$0.9769
$1.77
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, NTRA, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.63 | 1.22B | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
693.03 | 256.25B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
233.33 | 164.03B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.88 | 58.94B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
177.47 | 50.03B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
274.97 | 45.26B | 16.63B | 1.39B | 2.12B | 8.0674 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2026-04-29 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2025-11-20 | 개시 | JP Morgan | Neutral |
| 2025-10-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-25 | 개시 | JP Morgan | Neutral |
| 2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
| 2019-11-25 | 개시 | Piper Jaffray | Overweight |
| 2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 재확인 | Standpoint Research | Buy |
| 2016-06-03 | 개시 | Standpoint Research | Buy |
| 2016-03-31 | 재확인 | Barrington Research | Outperform |
| 2015-10-16 | 개시 | JP Morgan | Overweight |
| 2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 재확인 | Oppenheimer | Outperform |
| 2014-03-14 | 개시 | Oppenheimer | Outperform |
| 2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-10-22 | 개시 | Barrington Research | Outperform |
| 2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy - Zacks Investment Research
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI - Zacks Investment Research
GEHC Expands Theranostics Imaging With 5 Global Collaborations - Zacks Investment Research
Revvity Launches Signals LabGistics to Coordinate Scientific Workflows - Zacks Investment Research
3 Promising Penny Stocks With Over $200M Market Cap - Simply Wall Street
Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp - PR Newswire
H.C. Wainwright keeps USD 3.00 target for OPKO Health stock - AD HOC NEWS
OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides - Yahoo Finance
Barrington sets USD 2.25 target for OPKO Health stock - ad-hoc-news.de
Is OPKO Health (OPK) Pricing In Too Much For Sales? - Yahoo Finance
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - Zacks Investment Research
Opko Health Inc. (OPK) Stock Price | Live Quotes & Charts | NASDAQ - Timothy Sykes
Piper Sandler raises Opko Health stock price target on LabCorp deal - Investing.com
OPKO Health (NASDAQ:OPK) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - Zacks Investment Research
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M - TradingView
Opko Health stock hits 52-week high at 1.75 USD By Investing.com - Investing.com Canada
Ladder Capital Posts Upbeat Q3 Earnings, Joins Alcoa, Hyster-Yale And Other Big Stocks Moving Higher On Friday - Benzinga
Opko Health stock hits 52-week high at 1.75 USD - Investing.com
H.C. Wainwright reiterates Opko Health stock rating on Labcorp deal By Investing.com - Investing.com Canada
OPKO HEALTH, INC. : BARRINGTON RESEARCH RAISES TO OUTPERFORM FROM MARKET PERFORM - Moomoo
OPKO Health (NASDAQ:OPK) Stock Rating Raised to Outperform at Barrington Research - MarketBeat
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Why Is Opko Health Stock Gaining Thursday?OPKO Health (NASDAQ:OPK), Labcorp Holdings (NYSE:LH) - Benzinga
OPKO Health (NASDAQ:OPK) Shares Gap UpWhat's Next? - MarketBeat
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care - Zacks Investment Research
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday - Benzinga
OPK Stock Slides As Charts Flash Potential Pivot Zone - Timothy Sykes
Opko Health stock soars on $722M BioReference asset sale - Investing.com
OPK Stock Slides As Traders Weigh Weak Cash Flow And Support Levels - Timothy Sykes
Labcorp to buy select assets from Opko Health unit for up to $872 million - Reuters
OPK Stock Slips As Traders Weigh Weak Margins And Support Levels - StocksToTrade
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health - PR Newswire
A prostate cancer blood test may reach more patients if Labcorp completes its deal - Stock Titan
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? - Zacks Investment Research
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now - Zacks Investment Research
Hims & Hers Expands Australian Women's Health Platform With Hers - Zacks Investment Research
OPKO Health (NASDAQ:OPK) Share Price Breaks Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Here's Why You Should Add Avantor Stock to Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health Q3 2026 Earnings Date and Estimates - MarketBeat
Bruker Gains 66.3% in a Year: What's Driving the Rally? - Zacks Investment Research
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research - Zacks Investment Research
Here's Why You Should Retain WAT Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health stock gets Zacks upgrade while shares fall 4.79 percent - AD HOC NEWS
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Reasons to Add Globus Medical Stock to Your Portfolio Now - Zacks Investment Research
OPKO Health (NasdaqGS:OPK) Stock Forecast & Analyst Predictions - Simply Wall Street
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opko Health Inc 주식 (OPK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
0.39%
1.89%
자본화:
|
볼륨(24시간):